Literature DB >> 31461750

Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer.

Alberto Carmona-Bayonas1, Paula Jimenez-Fonseca2, Marcelo Garrido3, Ana Custodio4, Raquel Hernandez5, Alejandra Lacalle6, Juana María Cano7, Gema Aguado8, Eva Martínez de Castro9, Felipe Alvarez Manceñido10, Ismael Macias11, Laura Visa12, Marta Martín Richard13, Monserrat Mangas14, Manuel Sánchez Cánovas1, Federico Longo15, Leticia Iglesias Rey16, Nieves Martínez Lago17, Alfonso Martín Carnicero18, Ana Sánchez19, Aitor Azkárate20, María Luisa Limón21, Carolina Hernández Pérez22, Avinash Ramchandani23, Paola Pimentel24, Paula Cerdá25, Raquel Serrano26, Aitziber Gil-Negrete27, Miguel Marín28, Alicia Hurtado29, Rodrigo Sánchez Bayona30, Javier Gallego31.   

Abstract

Research into cancer-associated thrombosis (CAT) entails managing dynamic data that pose an analytical challenge. Thus, methods that assume proportional hazards to investigate prognosis entail a risk of misinterpreting or overlooking key traits or time-varying effects. We examined the AGAMENON registry, which collects data from 2,129 patients with advanced gastric cancer. An accelerated failure time (AFT) multistate model and flexible competing risks regression were used to scrutinize the time-varying effect of CAT, as well as to estimate how covariates dynamically predict cumulative incidence. The AFT model revealed that thrombosis shortened progression-free survival and overall survival with adjusted time ratios of 0.72 and 0.56, respectively. Nevertheless, its prognostic effect was nonproportional and disappeared over time if the subject managed to survive long enough. CAT that occurred later had a more pronounced prognostic effect. In the flexible competing risks model, multiple covariates were seen to have significant time-varying effects on the cumulative incidence of CAT (Khorana score, secondary thromboprophylaxis, high tumor burden, and cisplatin-containing regimen), whereas other predictors exerted a constant effect (signet ring cells and primary thromboprophylaxis). The model that assumes proportional hazards was incapable of capturing the effect of these covariates and predicted the cumulative incidence in a biased way. This study evinces that flexible and multistate models are a useful and innovative method to describe the dynamic effect of variables associated with CAT and should be more widely used. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31461750     DOI: 10.1055/s-0039-1694012

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.

Authors:  Sena Valcarcel; Javier Gallego; Paula Jimenez-Fonseca; Marc Diez; Eva Martínez de Castro; Raquel Hernandez; Virginia Arrazubi; Ana Custodio; Juana María Cano; Ana Fernández Montes; Ismael Macias; Laura Visa; Aitana Calvo; Rosario Vidal Tocino; Nieves Martínez Lago; María Luisa Limón; Mónica Granja; Mireia Gil; Paola Pimentel; Lola Macia-Rivas; Carolina Hernández Pérez; Montserrat Mangas; Alfonso Martín Carnicero; Paula Cerdà; Lucía Gomez Gonzalez; Francisco Garcia Navalon; Mª Dolores Mediano Rambla; Marta Martin Richard; Alberto Carmona-Bayonas
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-30       Impact factor: 4.322

2.  Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.

Authors:  J Gallego Plazas; A Arias-Martinez; A Lecumberri; E Martínez de Castro; A Custodio; J M Cano; R Hernandez; A F Montes; I Macias; A Pieras-Lopez; M Diez; L Visa; R V Tocino; N Martínez Lago; M L Limón; M Gil; P Pimentel; M Mangas; M Granja; A M Carnicero; C Hernández Pérez; L G Gonzalez; P Jimenez-Fonseca; A Carmona-Bayonas
Journal:  ESMO Open       Date:  2022-06-14

3.  Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study.

Authors:  Florian Posch; Julia Riedl; Eva-Maria Reitter; Michael J Crowther; Ella Grilz; Peter Quehenberger; Bernd Jilma; Ingrid Pabinger; Cihan Ay
Journal:  J Thromb Haemost       Date:  2020-04-15       Impact factor: 5.824

4.  External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.

Authors:  Paula Jimenez-Fonseca; Alberto Carmona-Bayonas; Alba Martinez-Torron; Maria Alsina; Ana Custodio; Olbia Serra; Diego Cacho Lavin; María Luisa Limón; Tamara Sauri; Flora López; Laura Visa; Mónica Granja; Nieves Martínez Lago; Virginia Arrazubi; Rosario Vidal Tocino; Raquel Hernandez; Gema Aguado; Juana María Cano; Alfonso Martín Carnicero; Monserrat Mangas; Paola Pimentel; Ana Fernández Montes; Ismael Macias Declara; Federico Longo; Avinash Ramchandani; Marta Martín Richard; Alicia Hurtado; Aitor Azkarate; Carolina Hernández Pérez; Raquel Serrano; Javier Gallego
Journal:  Ther Adv Med Oncol       Date:  2021-06-17       Impact factor: 8.168

5.  Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.

Authors:  Almudena Cotes Sanchís; Javier Gallego; Raquel Hernandez; Virginia Arrazubi; Ana Custodio; Juana María Cano; Gema Aguado; Ismael Macias; Carlos Lopez; Flora López; Laura Visa; Marcelo Garrido; Nieves Martínez Lago; Ana Fernández Montes; María Luisa Limón; Aitor Azkárate; Paola Pimentel; Pablo Reguera; Avinash Ramchandani; Juan Diego Cacho; Alfonso Martín Carnicero; Mónica Granja; Marta Martín Richard; Carolina Hernández Pérez; Alicia Hurtado; Olbia Serra; Elvira Buxo; Rosario Vidal Tocino; Paula Jimenez-Fonseca; Alberto Carmona-Bayonas
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

6.  Dynamics of D-dimer in non-small cell lung cancer patients receiving radical surgery and its association with postoperative venous thromboembolism.

Authors:  Lihui Ke; Songping Cui; Shuo Chen; Bin Hu; Hui Li
Journal:  Thorac Cancer       Date:  2020-07-13       Impact factor: 3.500

7.  External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

Authors:  Paula Jimenez-Fonseca; Alberto Carmona-Bayonas; Eva Martínez de Castro; Ana Custodio; Carles Pericay Pijaume; Raquel Hernandez; Gema Aguado; Natalia Castro Unanua; Juana María Cano; Flora López; Marcelo Garrido; Ana Fernández Montes; Laura Visa; Manuel Sánchez Cánovas; María Luisa Limón; Nieves Martínez Lago; Paola Pimentel; Alicia Hurtado; Aitor Azkárate; Federico Longo; Marc Diez; Aranzazu Arias-Martinez; Tamara Sauri; Alfonso Martín Carnicero; Monserrat Mangas; Marta Martín Richard; Mónica Granja; Avinash Ramchandani; Carolina Hernández Pérez; Paula Cerdá; Aitziber Gil-Negrete; Mariona Calvo; Rosario Vidal Tocino; Javier Gallego
Journal:  Gastric Cancer       Date:  2020-09-24       Impact factor: 7.370

8.  Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry.

Authors:  David Zaragoza-Huesca; Pedro Garrido-Rodríguez; Paula Jiménez-Fonseca; Eva Martínez de Castro; Manuel Sánchez-Cánovas; Laura Visa; Ana Custodio; Ana Fernández-Montes; Julia Peñas-Martínez; Patricia Morales Del Burgo; Javier Gallego; Ginés Luengo-Gil; Vicente Vicente; Irene Martínez-Martínez; Alberto Carmona-Bayonas
Journal:  Biomedicines       Date:  2022-01-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.